NCT06569225View on ClinicalTrials.gov

Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Cholangiocarcinoma Resectable
Interventions
DRUG

Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig

: Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase

Trial Locations (1)

M5G 2C4

University Health Network, Toronto General Hospital, Toronto

All Listed Sponsors
collaborator

Sunnybrook Health Sciences Centre

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

University Health Network, Toronto

OTHER